PMA device
AMS Ambicor Inflatable Penile Prosthesis
Boston Scientific Corp · Prosthesis, Penis, Inflatable (JCW, Class III) · First FDA decision Mar 28, 2019, newest Mar 28, 2019Erectile dysfunction
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "AMS Ambicor"
MAUDE reports
988
Brand "AMS Ambicor", since 2015
PubMed studies
9
Mentioning "AMS Ambicor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing AMS Ambicor Inflatable Penile Prosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- AMS Ambicor Inflatable Penile ProsthesisPMA supplement
N970012-S161 · Decided Mar 28, 2019 · 16 days after receipt · Normal 180 Day Track No User Fee
Device type: Prosthesis, penis, inflatable (JCW) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "AMS Ambicor", any status and sponsor, newest update first.
- IT Matters: The Erectile Restoration RegistryEnrolling by invitation
Boston Scientific CorporationPublic (BSX)
NCT04200937 · 450 participants (planned) · Start Aug 5, 2021 · Primary completion Jan 2031
Device: Tactra Malleable; Spectra™ Concealable Penile Prothesis and 3 more · For: Erectile Dysfunction
Sites: Los Angeles, California; Miami, Florida; Tampa, Florida · 25 sites in all
Boston Scientific CorporationPublic (BSX)
NCT01383018 · 1,457 participants · Start Jun 13, 2011 · Primary completion Nov 30, 2017
Device: AMS Penile Prosthesis Devices · For: Erectile Dysfunction; Impotence
Sites: Homewood, Alabama; Mountain View, California; San Diego, California · 11 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "AMS Ambicor", and for the whole product code for context.
This brand
988 reports: 105 malfunction, 883 injury, 0 death
Whole product code JCW
3,286 reports: 191 malfunction, 3,092 injury, 1 death
Newest reports for this brand
2124215-2026-57176 · Received Oct 28, 2026 · Event dated Oct 7, 2026
Device type: Device, Impotence, Mechanical/Hydraulic (FHW)
Device problem as coded: Mechanical Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- AMS AmbicorInjury
2124215-2026-57397 · Received Oct 28, 2026 · Event dated Oct 14, 2026
Device type: Device, Impotence, Mechanical/Hydraulic (FHW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Erosion; Pain
- AMS AmbicorInjury
2124215-2026-55346 · Received Oct 19, 2026 · Event dated Sep 22, 2026
Device type: Device, Impotence, Mechanical/Hydraulic (FHW)
Device problem as coded: Fluid/Blood Leak; Fracture; Mechanical Problem; Material Puncture/Hole
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "AMS Ambicor"[tiab]. The summary above synthesizes these.
- Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany.
Natali A, Olianas R, Fisch M · J Sex Med · 2008
- Life quality change after inflatable penile prosthesis implantation.
Ure I, Ozen A, Can C · Aging Male · 2020
- Surgical Outcomes of Erectile Implants After Phalloplasty: Retrospective Analysis of 95 Procedures.
Neuville P, Morel-Journel N, Maucourt-Boulch D, et al. · J Sex Med · 2016
- Placement of Inflatable Penile Implants in Patients With Prior Radical Pelvic Surgery: A Literature Review.
Madiraju SK, Hakky TS, Perito PE, et al. · Sex Med Rev · 2019Review
- A Retrospective Cohort Study on Surgical Outcomes of Penile Prosthesis Implantation Surgery in Transgender Men After Phalloplasty.
van der Sluis WB, Pigot GLS, Al-Tamimi M, et al. · Urology · 2019
- Insertion of inflatable penile prosthesis in the neophallus of assigned female at birth individuals: a systematic review of surgical techniques, complications and outcomes.
Pang KH, Christopher N, Ralph DJ, et al. · Ther Adv Urol · 2023Review
- Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: An Italian multicentric study.
Gentile G, Franceschelli A, Massenio P, et al. · Arch Ital Urol Androl · 2016Multicenter Study
- [Penile prosthesis. Quality outcomes and morbidity].
Chiva Robles V, Llanes González L, Pascual Mateo C, et al. · Arch Esp Urol · 2005English Abstract
- [Inflatable penile prosthesis: satisfaction rate, result, prognostic factors. Prospective study on 50 primooperated patients in CHU of Nice between 2000 and 2009].
Obadia F, Mouracade P, Terrier JE, et al. · Prog Urol · 2013English Abstract
Other devices of this type
Also filed under product code JCW.
- AMS 700 Inflatable Penile Prosthesis (with and without InhibiZone)Boston Scientific Corp · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.